Analyst Price Target is $24.75
▲ +362.62% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Checkmate Pharmaceuticals in the last 3 months. The average price target is $24.75, with a high forecast of $32.00 and a low forecast of $19.00. The average price target represents a 362.62% upside from the last price of $5.35.
Current Consensus is
The current consensus among 4 polled investment analysts is to buy stock in Checkmate Pharmaceuticals.
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naÃ¯ve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.